These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 21284360)

  • 1. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
    Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
    Hennekens CH; Sechenova O; Hollar D; Serebruany VL
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
    Berger JS; Brown DL; Becker RC
    Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for primary prevention of cardiovascular disease?
    Drug Ther Bull; 2009 Nov; 47(11):122-5. PubMed ID: 19887685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin for the prevention of cardiovascular morbidity.
    Sanchez-Ross M; Waller AH; Maher J; Klapholz M; Haider B; Kaluski E
    Minerva Med; 2010 Aug; 101(4):205-14. PubMed ID: 21030934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
    BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study.
    Welin L; Wilhelmsen L; Björnberg A; Odén A
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1143-9. PubMed ID: 19672841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of low-dose aspirin in polycythemia vera.
    Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T;
    N Engl J Med; 2004 Jan; 350(2):114-24. PubMed ID: 14711910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.
    Jardine MJ; Ninomiya T; Perkovic V; Cass A; Turnbull F; Gallagher MP; Zoungas S; Lambers Heerspink HJ; Chalmers J; Zanchetti A
    J Am Coll Cardiol; 2010 Sep; 56(12):956-65. PubMed ID: 20828648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.